Abstract
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.
Keywords: PI3K, inflammation, allergy, asthma, rheumatoid arthritis, COPD
Current Topics in Medicinal Chemistry
Title: Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Volume: 9 Issue: 8
Author(s): Michael K. Ameriks and Jennifer D. Venable
Affiliation:
Keywords: PI3K, inflammation, allergy, asthma, rheumatoid arthritis, COPD
Abstract: In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.
Export Options
About this article
Cite this article as:
Ameriks K. Michael and Venable D. Jennifer, Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ, Current Topics in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/156802609789044434
DOI https://dx.doi.org/10.2174/156802609789044434 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comprehensive Review of the Genus Pyrola Herbs in Traditional Uses, Phytochemistry and Pharmacological Activities
Current Topics in Medicinal Chemistry Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Skeletal Effects of Systemic and Topical Corticosteroids
Current Drug Safety Rationally Designed Multitarget Agents Against Inflammation and Pain
Current Medicinal Chemistry Anti-HER2 VHH Targeted Fluorescent Liposome as Bimodal Nanoparticle for Drug Delivery and Optical Imaging
Recent Patents on Anti-Cancer Drug Discovery Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
Current Pharmaceutical Biotechnology Personalizing Medicine from Birth: Are Countries Prepared for the Ethical, Legal, and Social Challenges?
Current Pharmacogenomics and Personalized Medicine Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design Accelerating Drug Discovery by Integrative Implementation of Laboratory Automation in the Work Flow
Current Medicinal Chemistry Trimetazidine Dihydrochloride Pulsatile–Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation
Current Drug Delivery TLR3 and TLR4 But not TLR2 are Involved in Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines Production Through Promoting the Production of Mitochondrial Reactive Oxygen Species
Current Molecular Medicine The Role of WNT in Rheumatoid Arthritis and its Therapeutic Implication
Mini-Reviews in Medicinal Chemistry Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy Novel MK2 Inhibitors by Fragment Screening
Combinatorial Chemistry & High Throughput Screening The Yin and Yang of the Ghrelin Gene Products
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Inflammatory Activity and Cheminformatics Analysis of New Potent 2-Substituted 1-Methyl-5-Nitroindazolinones
Current Topics in Medicinal Chemistry Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design Integration of Virtual and High Throughput Screening in Lead Discovery Settings
Combinatorial Chemistry & High Throughput Screening